Category - Developments

Developments

Can-Fite unit fails Phase 2 glaucoma trial

Can-Fite BioPharma’s (NYSE MKT:CANF; TASE:CFBI) subsidiary, OphthaliX (OTC:OPLI) released top-line results from its Phase 2 clinical trial of CF101 for the treatment of glaucoma. No statistically significant differences...

July 5, 2016

Developments

Titan Pharma added to Russell 3000 index

Titan Pharmaceuticals (NASDAQ:TTNP) has been added to the broad U.S. market Russell 3000 index and the small-cap Russell 2000 index as part of Russell Investments’ annual reconstitution of its stock indexes, effective...

June 27, 2016

Developments

Cellectar shows potential against triple negative breast cancer

Cellectar Biosciences (NASDAQ:CLRB) has announced the results of the first phase of a NCI-funded Small Business Innovation Research (SBIR) Phase 1 contract for a study of CLR 125, a radiotherapeutic isotope, which may...

June 23, 2016

Developments

Anavex gets orphan drug status for infantile spasms

Anavex Life Sciences (NASDAQ:AVXL) has received FDA orphan drug designation for ANAVEX 2-73 for the treatment of infantile spasms. ANAVEX 2-73 already has orphan drug designation for the treatment of Rett syndrome. An...

June 22, 2016

Developments

Profound Medical, Royal Philips sell TULSA-PRO in Germany

Profound Medical (TSX-V:PRN) and Royal Philips have jointly sold a TULSA-PRO system to University Hospital of Cologne, the first sale in Germany, following CE Mark approval in April 2016. TULSA-PRO is an innovative...

June 21, 2016

Developments

OrbiMed joins Round B NovellusDx financing

OrbiMed will join a $10-million financing round by closely-held NovellusDx led by IntraCure, a public life science holding company, and Pontifax, a leading Israeli life sciences VC, raising the size of the round to $12...

June 21, 2016

Developments

Oramed gets milestone payment from HTIT

Oramed Pharmaceuticals (NASDAQ:ORMP) has received a $6.5-million milestone payment from Hefei Tianhui Incubator of Technologies (HTIT) under a December 2015 license and investment agreement. The payment follows Oramed’s...

June 21, 2016

Developments

First patients treated with Titan Pharma’s Probuphine

The first 10 patients received treatment last week with Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant of buprenorphine, following FDA approval on May 26. ProbuphineProbuphine was developed using Titan’s long...

June 20, 2016

Developments

Avivagen reports new livestock trials with OxC-beta

Avivagen (TSX-V:VIV) has provided results of four new trials of OxC-beta livestock as a feed additive for swine in the Philippines and Vietnam, and broiler poultry in the Philippines and Spain. In a new trial with the...

June 20, 2016

Developments

Dipexium Pharma presents new Locilex microbiology data

Dipexium Pharmaceuticals (NASDAQ:DPRX) and research collaborator, R. M. Alden Research Laboratory, presented data from two new Locilex microbiology studies at the American Society for Microbiology’s Microbe conference...

June 20, 2016

Category - Developments

Can-Fite unit fails Phase 2 glaucoma trial

Titan Pharma added to Russell 3000 index

Cellectar shows potential against triple negative breast cancer

Anavex gets orphan drug status for infantile spasms

Profound Medical, Royal Philips sell TULSA-PRO in Germany

OrbiMed joins Round B NovellusDx financing

Oramed gets milestone payment from HTIT

First patients treated with Titan Pharma’s Probuphine

Avivagen reports new livestock trials with OxC-beta

Dipexium Pharma presents new Locilex microbiology data

General

More